Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.neulandlabs.com | |
Market Cap | 9,647.95 Cr. | |
Enterprise Value(EV) | 9,606.90 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 247.13 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 30.43 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.15 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 945.65 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 7.95 | Calculated using Price: 7,519.90 |
Dividend Yield | 0.13 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.28 Cr. | 12,829,889 Shares |
FaceValue | 10 | |
About Neuland Laboratories Ltd. | ||
Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe. |
1 Day |
|
+5.48% |
1 Week |
|
+23.97% |
1 Month |
|
+26.67% |
3 Month |
|
+32.67% |
6 Month |
|
+94.22% |
1 Year |
|
+260.69% |
2 Year |
|
+427.07% |
5 Year |
|
+996.03% |
10 Year |
|
+2906.52% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 11.24 | 15.64 | 22.34 | 5.02 | 3.48 | 2.3 | 10.79 | 7.85 | 17.84 | |
Return on Capital Employed (%) | 15.75 | 18.57 | 15.98 | 4.07 | 3.99 | 7.85 | 12.81 | 9.44 | 20.94 | |
Return on Assets (%) | 3.2 | 5.23 | 6.65 | 1.23 | 1.49 | 1.37 | 6.31 | 4.71 | 11.04 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 161 | 187 | 546 | 558 | 699 | 710 | 786 | 841 | 994 | 1,133 | |
Non Curr. Liab. | 55 | 69 | 54 | 146 | 104 | 163 | 170 | 180 | 147 | 129 | |
Curr. Liab. | 295 | 268 | 286 | 367 | 327 | 358 | 369 | 363 | 439 | 403 | |
Minority Int. | 0 | ||||||||||
Equity & Liab. | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,665 | |
Non Curr. Assets | 196 | 210 | 511 | 624 | 677 | 716 | 775 | 803 | 819 | 831 | |
Curr. Assets | 316 | 314 | 375 | 447 | 453 | 515 | 550 | 581 | 761 | 834 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,665 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,581 | |
Other Income | 1 | 2 | 1 | 5 | 3 | 4 | 16 | 2 | 10 | 15 | |
Total Income | 470 | 512 | 580 | 532 | 670 | 767 | 953 | 953 | 1,201 | 1,596 | |
Total Expenditure | -403 | -430 | -473 | -477 | -608 | -661 | -790 | -808 | -919 | -1,105 | |
PBIDT | 67 | 82 | 108 | 55 | 62 | 106 | 163 | 145 | 282 | 491 | |
Interest | -27 | -24 | -21 | -19 | -16 | -22 | -18 | -14 | -13 | -15 | |
Depreciation | -15 | -16 | -19 | -22 | -26 | -31 | -40 | -49 | -53 | -57 | |
Taxation | -9 | -15 | -20 | -2 | -4 | -37 | -25 | -18 | -52 | -102 | |
Exceptional Items | |||||||||||
PAT | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 317 | |
Minority Interest | 0 | 0 | |||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 317 | |
Adjusted EPS | 18 | 31 | 53 | 14 | 13 | 13 | 63 | 50 | 127 | 246 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 49 | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | |
Cash Fr. Inv. | -10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -96 | -62 | |
Cash Fr. Finan. | -39 | 1 | -24 | 0 | 105 | 12 | -5 | -114 | 38 | -136 | |
Net Change | 0 | 0 | 1 | -4 | 0 | 5 | 3 | -9 | 3 | 40 | |
Cash & Cash Eqvt | 1 | 1 | 2 | 3 | 3 | 8 | 11 | 2 | 5 | 45 |
Fri, 12 Apr 2024
Certificate Under Regulation 40(10) Of SEBI(LODR) Regulations 2015 Certificate under Regulation 40(10) of SEBI (LODR) Regulations 2015 |
Wed, 03 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018 |
Wed, 03 Apr 2024
Compliance Certificate- Regulation 7(3) Of SEBI(LODR) Regulations 2015 For The Year Ended March 31 2024 Compliance Certificate - Regulation 7(3) of SEBI (LODR) Regulations 2015 for the year ended March 31 2024 |
Tue, 16 Apr 2024 |
Higher Delivery Quantity |
Higher Trade Quantity |
Higher Trade and Delivery Quantity |
Close Crossing 52 Week High |
Closing Above Previous High |